This disease status became relevant when novel imaging modalities, such as prostate specific membrane antigen positron emission tomography (PSMA-PET), were introduced with better tumor detection rates compared to the conventional scans (e.g. CT or bone scans) [14, 15]. This evidence concerns the gene FOLH1 and neoplasm.